NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.4b

Last Updated

2021/05/16 00:00 UTC

Data Sources

Company Financials +

Executive Summary

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Castle Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CSTL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CSTL's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-8.5%

CSTL

-2.0%

US Healthcare

-1.7%

US Market


1 Year Return

47.3%

CSTL

39.3%

US Healthcare

50.8%

US Market

Return vs Industry: CSTL exceeded the US Healthcare industry which returned 39.4% over the past year.

Return vs Market: CSTL underperformed the US Market which returned 50.5% over the past year.


Shareholder returns

CSTLIndustryMarket
7 Day-8.5%-2.0%-1.7%
30 Day-19.1%4.1%-1.2%
90 Day-42.3%14.7%0.4%
1 Year47.3%47.3%41.1%39.3%53.3%50.8%
3 Yearn/a59.9%53.4%61.5%51.4%
5 Yearn/a108.8%93.2%125.9%100.7%

Long-Term Price Volatility Vs. Market

How volatile is Castle Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Castle Biosciences undervalued compared to its fair value and its price relative to the market?

3.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CSTL ($55.17) is trading above our estimate of fair value ($10.17)

Significantly Below Fair Value: CSTL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CSTL is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: CSTL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CSTL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CSTL is good value based on its PB Ratio (3.3x) compared to the US Healthcare industry average (3.5x).


Future Growth

How is Castle Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

78.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CSTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CSTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CSTL's revenue (30% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CSTL's revenue (30% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CSTL is forecast to be unprofitable in 3 years.


Past Performance

How has Castle Biosciences performed over the past 5 years?

78.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CSTL is currently unprofitable.

Growing Profit Margin: CSTL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CSTL is unprofitable, but has reduced losses over the past 5 years at a rate of 78% per year.

Accelerating Growth: Unable to compare CSTL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CSTL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (59.7%).


Return on Equity

High ROE: CSTL has a negative Return on Equity (-3.62%), as it is currently unprofitable.


Financial Health

How is Castle Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: CSTL's short term assets ($426.7M) exceed its short term liabilities ($17.6M).

Long Term Liabilities: CSTL's short term assets ($426.7M) exceed its long term liabilities ($1.2M).


Debt to Equity History and Analysis

Debt Level: CSTL is debt free.

Reducing Debt: CSTL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CSTL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CSTL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 132.2% per year.


Dividend

What is Castle Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CSTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CSTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CSTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSTL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CSTL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Derek Maetzold (58 yo)

13.67yrs

Tenure

US$5,344,639

Compensation

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. Mr. Maetzold served as the Vice Presi...


CEO Compensation Analysis

Compensation vs Market: Derek's total compensation ($USD5.34M) is above average for companies of similar size in the US market ($USD3.78M).

Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CSTL's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: CSTL's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.5%.


Top Shareholders

Company Information

Castle Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Castle Biosciences, Inc.
  • Ticker: CSTL
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.382b
  • Shares outstanding: 25.06m
  • Website: https://castlebiosciences.com

Number of Employees


Location

  • Castle Biosciences, Inc.
  • 820 South Friendswood Drive
  • Suite 201
  • Friendswood
  • Texas
  • 77546
  • United States

Listings


Biography

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a mul...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/16 00:00
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.